Exchange & Returns Information
Review Details
(2)
| Generic For | OPDIVO |
|---|---|
| Active Ingredient | NIVOLUMAB |
| Strength | 240MG |
| Manufacturer | BRISTOL MYERS SQUIBB |
| Pack Size | Price Per Unit | Unit Price | QTY | CART | Best Coupon Price MAX DISCOUNT |
|---|---|---|---|---|---|
| 1 BOX - 1 VIAL | $ 1,307.00 | $ 1,307.00 |
$ 1,110.95
Apply ZARVY26 (-15%)
You save $ 196.05
|
||
| 2 BOXES - 2 VIALS | $ 1,296.00 |
1% $ 2,614.00
$ 2,592.00
|
$ 2,203.20
Apply ZARVY26 (-15%)
You save $ 388.80
|
||
| ★ Best Value 3 BOXES - 3 VIALS | $ 1,287.33 |
2% $ 3,921.00
$ 3,862.00
|
$ 3,282.70
Apply ZARVY26 (-15%)
You save $ 579.30
|
Reference information will be available soon.
Opdyta 240mg, solution for injection is a mid-to-high dose presentation of Nivolumab, a PD-1 immune checkpoint inhibitor widely used in oncology. It is administered intravenously and works by restoring anti-tumor immunity through blocking the PD-1 receptor pathway on T-cells. The 240mg formulation offers a convenient dosing option for adult cancer patients across a wide range of indications, minimizing dose adjustments and reducing vial wastage. It is frequently used as a standalone regimen or in combination protocols, particularly with Ipilimumab or chemotherapy agents.
- AntiCancer Drugs > Lung Cancer (NSCLC, Mesothelioma) Nivolumab is indicated for both monotherapy and combination therapy in advanced non-small cell lung cancer, improving survival in patients with PD-L1 expression or those previously treated. Also approved for malignant pleural mesothelioma when used with Ipilimumab. > Skin Cancer (Melanoma) Used in both metastatic and resected melanoma, Nivolumab is effective as a single agent or when combined with Ipilimumab. The 240mg dose is optimal for biweekly administration in long-term maintenance. > Kidney Cancer (RCC) An essential drug for advanced renal cell carcinoma, where it’s administered as monotherapy or with Ipilimumab or Cabozantinib. Its immunologic mechanism enhances tumor control in poor-risk patients. > Head and Neck Squamous Cell Carcinoma (HNSCC) Offers prolonged survival benefits in recurrent/metastatic HNSCC post-platinum therapy. Used alone or in combination immunotherapy schedules. > Liver Cancer (Hepatocellular Carcinoma) Used in patients previously treated with sorafenib. When paired with Ipilimumab, it provides a durable immune-mediated response in HCC. > Blood Cancer (Hodgkin Lymphoma) Approved for relapsed or refractory Hodgkin’s lymphoma with high response rates even in post-transplant patients. The 240mg dose is used in standard adult protocols. > Urothelial, Esophageal, Gastric, and Colorectal Cancers A key option in immunotherapy-based regimens across GI and urologic malignancies. Especially effective in MSI-H/dMMR colorectal cancer and PD-L1 positive gastric and esophageal tumors.
Nivolumab functions by binding to the PD-1 receptor on T cells and blocking its interaction with PD-L1/PD-L2 ligands. This reactivates T cell cytotoxicity, enabling immune-mediated elimination of tumor cells. The 240mg vial facilitates fixed dosing every 2 weeks (q2w), offering consistent plasma levels for sustained immune activation. When combined with CTLA-4 blockade (Ipilimumab), it enhances both priming and effector phases of T-cell responses, increasing overall efficacy across several tumor types.
All doses must be administered as an intravenous infusion over 30 minutes. Dosage varies by indication, patient weight, and whether it is used alone or in combination. - Melanoma: • Monotherapy: 240 mg q2w or 480 mg q4w • Adjuvant: Same dosing up to 1 year • Combo: Ipi 3 mg/kg + Nivo 1 mg/kg q3w × 4 doses, then Nivo maintenance (240 mg q2w) - NSCLC: • Monotherapy: 240 mg q2w or 480 mg q4w • Combo: Nivo 3 mg/kg + Ipi 1 mg/kg q6w (PD-L1+) • Chemo Combo: Nivo 360 mg q3w + Ipi 1 mg/kg q6w + platinum-doublet × 2 cycles - RCC: • Monotherapy: 240 mg q2w • Combo: Nivo 3 mg/kg + Ipi 1 mg/kg q3w × 4 doses → Nivo 240 mg q2w • With Cabozantinib: Nivo 240 mg q2w + Cabo 40 mg PO daily - Hodgkin Lymphoma, HNSCC, Urothelial Cancer: • 240 mg q2w or 480 mg q4w - HCC: • Mono: 240 mg q2w or 480 mg q4w • Combo: Nivo 1 mg/kg + Ipi 3 mg/kg q3w × 4 doses → Nivo 240 mg q2w - Esophageal, Gastric & GEJ Cancers: • Mono: 240 mg q2w (up to 1 year) • Combo: Nivo + platinum/fluoropyrimidine q2w OR Nivo 360 mg q3w + chemo - Colorectal Cancer (Adult & Pediatric ≥12 yrs): • ≥40kg: 240 mg q2w or 480 mg q4w • <40kg: 3 mg/kg q2w • Combo: Nivo 3 mg/kg + Ipi 1 mg/kg q2w × 4 doses
Keep refrigerated at 2°C to 8°C. Do not freeze or shake. Protect from light. If diluted, the infusion solution should be used within 24 hours when stored between 2–8°C.
Immune-related side effects may include colitis, hepatitis, pneumonitis, endocrinopathies (e.g., thyroid dysfunction, adrenal insufficiency), and nephritis. Other adverse events include fatigue, rash, arthralgia, and infusion reactions. Monitor liver, thyroid, and renal function regularly. Immunosuppressants like corticosteroids may be required for severe immune-related events.
The vial reached me two days sooner than the quoted timeline, packed securely with no leaks or issues.
My order was once delayed at customs, but with the insurance option I received a full refund in just a few days. The customer service team explained each step clearly, making the process stress-free and giving me confidence to order again.
No combo deals available at the moment.
